Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

VRAX vs CING: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CING Captures Overall Composite Edge (44.8 HOLD vs 41.7 SELL), While VRAX Leads 3–2 on Growth & Valuation Pillars

CING Overall Winner 6-Pillar Tally: VRAX 3 – 2 CING (1 Tie) Matrix Metrics: VRAX 2 – 5 CING

As of Nov 17, 2026, Cingulate Inc. (CING) captures the overall head-to-head institutional edge over Virax Biolabs Group Limited (VRAX) on higher Unified Composite conviction (44.8/100 HOLD vs. 41.7/100 SELL) after splitting the core matrix 5–2 (led by Balance Sheet & Cash Flow, Options & Positioning), while VRAX wins 3–2 across the 6-pillar growth and valuation breakdown. VRAX trades at $0.46 (N/M Forward P/E, -51515.2% operating margin) versus CING at $4.72 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: CING earns the overall head-to-head edge with a stronger Unified Composite Score (44.8/100 HOLD vs. VRAX 41.7/100 SELL) and 1.07β · 121% Vol risk profile, whereas VRAX leads top-line expansion (+684.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: VRAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 18.9); meanwhile CING is in a Breakdown options structure phase (RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VRAX vs CING
VRAX NASDAQ
Virax Biolabs Group Limited Ordinary Shares
In Vitro & In Vivo Diagnostic Substances
$0.46
+2.46% 1D
Market Cap $823,939
TTM Revenue $12,423
Forward P/E N/M
Beta / 30D Vol -9.35β · 161% Vol
Unified Composite Score
41.7 / 100 SELL
Tech 25.0 Fund 44.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -30.6%), weak momentum, RSI 19
RSI-14: 18.9 · SMA20: $0.97 · SMA50: $1.70
CING NASDAQ Head-to-Head Winner
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.72
+26.0% 1D
Market Cap $62.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.07β · 121% Vol
Unified Composite Score
44.8 / 100 HOLD
Tech 31.0 Fund 50.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.9 · SMA20: $4.71 · SMA50: $4.82

6-Pillar Scorecard Institutional Category Breakdown (VRAX 3 – 2 CING)

Columns: Metric · VRAX · CING
1. Valuation Multiples VRAX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 66.3x N/M
2. Growth & Scale VRAX
Revenue Growth (YoY) +684.9% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $12,423 N/A
Market Cap $823,939 $62.5M
3. Profitability & Quality VRAX
Gross Margin 61.9% N/A
Operating Margin -51515.2% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -78.6% -198.7%
4. Balance Sheet & Cash Flow CING
Cash Generation (TTM) -$6.0M EBITDA -$21M
Cash Flow Margin N/A N/A
Net Cash / Leverage $13.08 Book/Sh · -78.6% ROE $22M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CING
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 111.1% (16th %ile)
Put/Call OI Skew N/A 0.07x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VRAX (2) vs CING (5)
Institutional Metric VRAX CING Criterion Row Edge
Market Capitalization
Scale
$823,939 $62.5M Larger Scale CING
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+684.9% +0.0% Higher Growth VRAX
Operating Margin (TTM)
Profitability
-51515.2% 0.0% Higher Margin CING
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-78.6% -198.7% Higher ROE VRAX
52-Week Range Position
Momentum
3% ($0–$13) 18% ($3–$12) Stronger Trend CING
Beta / 30D Volatility
Risk Regime
-9.35β · 161% Vol 1.07β · 121% Vol Lower Realized Risk CING
Unified Institutional Score
Composite Signal
41.7 / 100 (SELL) 44.8 / 100 (HOLD) Higher Composite CING
Trailing 12M Revenue (USD)
Operating Scale
$12,423 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
61.9% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 66.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$6.0M EBITDA ($13.08 Book/Sh · -78.6% ROE) -$21M ($22M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CING +75.58 pp
VRAX: -67.21% · CING: +8.37%
3M Horizon CING +75.23 pp
VRAX: -85.57% · CING: -10.34%
6M Horizon VRAX +40.91 pp
VRAX: +48.54% · CING: +7.63%
1Y Horizon CING +41.91 pp
VRAX: -6.52% · CING: +35.39%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VRAX vs CING. Trailing 12-month operating profitability (VRAX -51515.2% vs CING 0.0%) and valuation multiples (VRAX N/M vs CING N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VRAX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$12,423
Gross Margin61.9%
Op. Margin-51515.2%
ROE / Fwd P/E-78.6% · N/M
CING ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-198.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VRAX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VRAX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CING BREAKDOWN
170d in phase · OBV ACCUMULATION
Current IV 111.1%
IV Percentile 16th %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CING Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VRAX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $823,939 market capitalization and -51515.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CING Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $62.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VRAX vs CING Key Questions & Quantitative Answers

As of Nov 17, 2026, Cingulate Inc. (CING) captures the overall head-to-head institutional edge over Virax Biolabs Group Limited (VRAX) on higher Unified Composite conviction (44.8/100 HOLD vs. 41.7/100 SELL) after splitting the core matrix 5–2 (led by Balance Sheet & Cash Flow, Options & Positioning), while VRAX wins 3–2 across the 6-pillar growth and valuation breakdown. VRAX trades at $0.46 (N/M Forward P/E, -51515.2% operating margin) versus CING at $4.72 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: CING earns the overall head-to-head edge with a stronger Unified Composite Score (44.8/100 HOLD vs. VRAX 41.7/100 SELL) and 1.07β · 121% Vol risk profile, whereas VRAX leads top-line expansion (+684.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VRAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 18.9); meanwhile CING is in a Breakdown options structure phase (RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VRAX leads the Growth & Scale pillar: VRAX posts +684.9% YoY revenue growth and +0.0% YoY earnings growth on $12,423 TTM revenue (61.9% gross margin, -51515.2% operating margin), compared with CING at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, VRAX generates $12,423 in USD-normalized revenue versus N/A for CING. In operating R&D and SG&A reinvestment, VRAX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CING.

VRAX screens cheaper on headline valuation multiples. VRAX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 66.3x EV/Revenue (unreported EBITDA margin), whereas CING trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VRAX (-78.6% ROE) versus CING (-198.7% ROE) capital efficiency.

In options market volatility and institutional positioning, VRAX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.35β · 161% Vol realized risk). By comparison, CING carries 111.1% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.07β · 121% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.